Our job at Insider Financial is to have our fingers on the pulse of what’s happening in the penny stock world for our subscribers. Many of our subscribers are now sitting on over 1000% plus gains in TSNP, which you can read about here. The TSNP HUMBL merger is indeed a hot deal and there are more gains to come, especially once we get the shareholder update next month and the financials on HUMBL.
However, it’s important to know when to take some money off the table and also to hedge your bets. With all the excitement last week surrounding TSNP, one play that has gotten overlooked is the BioClonetics ENZC merger.
In our last write-up, we laid out the bull case on why the BioClonetics ENZC merger was the perfect deal. We suggest you take a read here if you have not read it yet. In this article, we are going to take a look at the new developments, particularly what’s happening with BioClonetics ENZC at Texas A&M University.
As we will discuss, Texas A&M University is ground-zero when it comes to the U.S. government’s efforts to get coronavirus treatments out to hundreds of millions of Americans.BioClonetics ENZC is about to be front and center of this effort and this is why ENZC shares are an absolute steal at these levels.
BioClonetics ENZC Merger
First up, here’s a little background info for those not familiar with the BioClonetics ENZC merger.
Enzolytics, Inc. is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Immunotech is committed to creating drugs for the better health of mankind. Enzolytics is a 49% shareholder of IMMB BG.
Enzolytics’ flagship compound ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.
BioClonetics Immunotherapeutics, Inc. is a Dallas Texas biotech company with proprietary technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases including HIV, rabies, influenza A, influenza B, tetanus, and diphtheria. Its proprietary methodology for produce fully human monoclonal antibodies may be used to produce therapeutics treatments for many infectious diseases including the CoronaVirus.
BioClonetics ENZC A Perfect Merger
As we discussed in our last article on BioClonetics ENZC, the combination is a perfect match.
BioClonetics Clone 3 recombinant mAbs will be combined with the Enzolytics’ flagship compound ITV-1, a suspension of Inactivated Pepsin Fragment (IPF), which studies have shown is effective in the treatment of HIV. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.
IPF is a platform technology that can be used to facilitate a broad range of applications. It is free from major neurological, gastrointestinal, and hematological side effects seen in the antiretrovirals in use today. IPF has been shown to not be subject to viral resistance and is cost-effective. Charles Cotropia, CEO of BioClonetics said:
“Our proprietary methodology may also be applied to produce monoclonal antibodies against other infectious diseases and the invitation by the National Science Foundation (NSF) to apply for funding to further BioClonetics efforts to develop anti-SARS-Cov-2 monoclonal antibodies using our proprietary technology is an exciting development for BioClonetics. We have previously produced monoclonal antibodies against HIV, rabies, influenza A, influenza B, tetanus, and diphtheria. We look forward to discovering how ENZC’s ITV-1 treatment can be used with our monoclonal antibody platform to synergistically improve our such antibodies for treating HIV.”
The Companies plan to conduct binding studies combining the therapeutics produced by both companies to evaluate the beneficial effects and increased binding capability of the BioClonetics Clone 3 antibodies to multiple HIV isolates.
Thereafter, additional PBMC based in-vitro neutralization studies will be conducted with the BioClonetics Clone 3 recombinant antibodies in combination with the Enzolytics ITV-1 peptide. Based on the results, the best combination will be tested in primate studies at the California National Primate Research Center University of California, Davis, California.
Texas A&M University
Earlier this month, BioClonetics ENZC announced that it was expanding its lab to the campus of Texas A&M University at its Institute for Preclinical Studies. This expansion will allow BioClonetics ENZC to complete the production of monoclonal antibodies against both the HIV virus and the CoronaVirus and collaborate with the biopharma experts on the campus.
We are quite familiar with Texas A&M University as one of our Spring Covid-19 runners was iBIO Inc and its FastPharming Facility at Texas A&M University. You can read our initial coverage here from April 28th. Our subscribers caught the move from $.80 to $7 in just 3 months!
Originally built in 2010 with funding from the U.S. Defense Advanced Research Projects Agency (DARPA), iBio’s FastPharming Facility was part of the “Blue Angel” initiative to establish factories capable of rapid delivery of medical countermeasures in response to a disease pandemic.
BARDA has gained prominence since the new coronavirus spread throughout the United States. BARDA was created in response to the terrorist attacks on Sept. 11, 2001, but the agency is turning its attention to the pandemic. The CARES Act, which was passed in March, included $3.5 billion for the Biomedical Advanced Research and Development Authority, an arm of the Department of Health and Human Services created to fight bioterrorism and pandemic diseases.
Putting the Pieces Together
The challenges related to COVID-19 are numerous. One of the biggest challenges is once a vaccine is found, how will that vaccine be manufactured in mass quantities.
Where has the US government chosen to mass-produce a COVID-19 vaccine?
The federal government has reserved a high-tech bio-manufacturing facility at Texas A&M University for mass production of a COVID-19 vaccine as part of a program implemented by President Donald Trump.
Who is coordinating the manufacturing?
If you guessed BARDA, you are correct again!
The Texas A&M System’s CIADM was one of three centers developed in the U.S. in response to the H1N1 influenza pandemic by BARDA.
BioClonetics ENZC Role
BioClonetics ENZC will now be collaborating with all the players at Texas A&M University. Experts agree that for a monoclonal antibody therapy to be effective, a “combination” (or “cocktail”) of such antibodies used in combination will likely be needed.
Dr. Anthony Fauci, head of NIAID/NIH, has repeatedly clarified (as recently in his keynote address at the AIDS International Conference) that success in the treatment of such viruses can be expected to be found in the use of multiple broadly neutralizing HIV antibodies – meaning several antibodies that neutralize a broad spectrum of a virus in its numerous mutation forms.
While other pharma companies may produce effective antibodies, there will necessarily be a need for additional monoclonal antibodies to be used in tantum with those initially discovered. Also, and unfortunately, the mutation of viruses, both the HIV and the CoronaVirus, will necessitate the production of numerous effective antibodies as the virus mutates around the therapeutics initially discovered.
The biggest concern with Covid-19 treatment is virus escape. This is when the antibody (over time) will be rendered ineffective due to mutation.
BioClonetics ENZC anti-HIV monoclonal antibody targets an immutable virus site on the HIV virus – one that is constant within virtually all 6000 now known different HIV isolates (strains) of the virus. The CoronaVirus has a structure correlative to that of the HIV virus.
BioClonetics ENZC primary anti-HIV monoclonal antibody has been proven to neutralize numerous different strains of the HIV virus in tests in 5 international labs. Knowing the binding site on the HIV virus to which its antibody binds resulting in neutralization, this knowledge provides the insight necessary to identifying corresponding structure (amino acid sequences) on the CoronaVirus that should be targeted to effectively neutralize the CoronaVirus.
BioClonetics ENZC Solution
Additional monoclonal antibodies can be expected to be needed to fully treat COVID-19 patients.
BioClonetics ENZC model starts with human “immune-B cells”, obtained from convalescent individuals who have recovered from the CoronaVirus. The primary distinction of the BioClonetics ENZC process for creating fully human monoclonals is the starting point – namely from human “immune-B cells” from humans who have survived successfully from a “natural” CoronaVirus infection. From there, the company can then produce antibodies that target conserved immutable sites on the virus – to avoid “virus escape”.
BioClonetics ENZC has a current market cap of just $25 million. This is incredibly cheap for a company that stands to be at the forefront of HIV/COVID-19 treatment. We are just waiting for the merger to close and for the company to receive its NIH grant money. We can also speculate with great certainty that the move to Texas A&M University is no coincidence. With DARPA involvement, we could also see Operation Warp Speed funding. All of these factors point to BioClonetics ENZC shares being an incredible bargain at current levels. While we know many are chasing TSNP right now, BioClonetics ENZC has multiple catalysts lined up to send shares parabolic.
As always, good luck to all (except the shorts)!
WHEN INSIDER FINANCIAL HAS A STOCK TIP, IT CAN PAY TO LISTEN. AFTER ALL, OUR FREE NEWSLETTER HAS FOUND MANY TRIPLE-DIGIT WINNERS FOR OUR SUBSCRIBERS. WE SPECIALIZE IN FINDING MOMENTUM BEFORE IT HAPPENS!
Disclosure: We have no position in OTCMKTS:ENZC, or any of the securities mentioned. We wrote this article ourselves and it expresses our own opinions. We are not receiving compensation for it. We have no business relationship with any company whose stock is mentioned in this article. Insider Financial is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This article is not a solicitation or recommendation to buy, sell, or hold securities. This article is meant for informational and educational purposes only and does not provide investment advice.